|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.50 GBX | +1.03% |
|
+4.12% | -16.19% |
| May. 15 | Syncona investee Spur reports "encouraging" drug trial data | AN |
| May. 07 | Syncona's Beacon Therapeutics receives positive data for XLRP therapy | AN |
| Capitalization | 538M 732M 633M 594M 994M 63B 1.12B 6.94B 2.7B 28.84B 2.75B 2.69B 105B | P/E ratio 2025 * |
3.91x | P/E ratio 2026 * | 2.49x |
|---|---|---|---|---|---|
| Enterprise value | 515M 700M 606M 568M 951M 60.3B 1.08B 6.64B 2.59B 27.6B 2.63B 2.57B 101B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
99.22% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Syncona Limited
More press releases
| 1 day | +1.03% | ||
| 1 week | +4.12% | ||
| Current month | +10.62% | ||
| 1 month | +1.72% | ||
| 3 months | -3.70% | ||
| 6 months | -13.91% | ||
| Current year | -16.19% |
| 1 week | 83.5 |  | 88.5 |
| 1 month | 79.6 | | 88.7 |
| Current year | 77.32 | | 104.54 |
| 1 year | 77.32 | | 126 |
| 3 years | 77.32 | | 213 |
| 5 years | 77.32 | | 280 |
| 10 years | 77.32 | | 306.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Annabel Clark
IRC | Investor Relations Contact | - | 2018-04-30 |
John Tsai
PRN | Corporate Officer/Principal | 58 | 2022-12-31 |
Lisa Bright
PRN | Corporate Officer/Principal | 58 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 2017-10-31 | |
Gian Reverberi
BRD | Director/Board Member | 59 | 2018-03-31 |
Melanie Gee
CHM | Chairman | 64 | 2019-06-03 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.03% | +4.12% | -19.84% | -52.93% | 732M | ||
| -1.33% | -3.43% | -2.51% | +45.69% | 88.84B | ||
| 0.00% | 0.00% | - | - | 15.38B | ||
| -0.08% | -1.22% | +69.58% | +186.19% | 18.19B | ||
| -2.48% | -4.83% | -17.50% | +16.79% | 16.45B | ||
| -1.10% | -2.40% | -3.94% | +44.00% | 15.49B | ||
| -1.87% | -0.90% | +50.62% | +293.21% | 14.32B | ||
| -0.82% | -0.66% | +6.50% | -1.73% | 12.65B | ||
| -2.34% | -4.93% | -9.66% | +8.99% | 12.2B | ||
| -1.30% | -1.17% | +7.87% | -9.71% | 9.88B | ||
| Average | -1.03% | -1.76% | +9.01% | +58.95% | 20.41B | |
| Weighted average by Cap. | -1.25% | -2.77% | +7.66% | +66.52% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | 145M 197M 170M 160M 268M 16.96B 303M 1.87B 727M 7.77B 740M 724M 28.37B | 224M 305M 264M 247M 414M 26.25B 468M 2.89B 1.13B 12.02B 1.14B 1.12B 43.9B |
| Net Debt | -23.1M -31.41M -27.17M -25.49M -42.65M -2.7B -48.24M -298M -116M -1.24B -118M -115M -4.52B | -32.96M -44.81M -38.76M -36.37M -60.85M -3.86B -68.83M -425M -165M -1.77B -168M -165M -6.45B |
More financial data
* Estimated data
Employees
1,050
Sector
Investment Holding Companies
Calendar
Jun. 19
- Q4 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-13 | 88.50 p | +1.03% | 306,379 |
| 25-06-12 | 87.60 p | +1.27% | 372,123 |
| 25-06-11 | 86.50 p | +0.35% | 441,334 |
| 25-06-10 | 86.20 p | +0.23% | 490,080 |
| 25-06-09 | 86.00 p | +1.18% | 186,400 |
Delayed Quote London S.E., June 13, 2025 at 11:35 am EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8850GBP
Average target price
2.250GBP
Spread / Average Target
+154.24%
Annual profits - Rate of surprise
- Stock Market
- Equities
- BACT Stock
Select your edition
All financial news and data tailored to specific country editions
